Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00358306
Recruitment Status : Completed
First Posted : July 31, 2006
Last Update Posted : May 14, 2020
Sponsor:
Information provided by (Responsible Party):
David Askenazi, University of Alabama at Birmingham

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To understand how AKI (Acute Kidney Injury) leads to chronic kidney disease so therapies can be found to alter the progression of events thereby significantly impacting the long-term outcomes of children who develop AKI.

Condition or disease
Acute Renal Failure Chronic Kidney Failure Endothelial Dysfunction Hemolytic-uremic Syndrome (HUS)

Detailed Description:
This research study is designed to study what happens to the kidneys after they have an injury. There is some evidence that even if there appears to be great improvement of kidney function, an injury can put patients at risk for long-term problems with their kidney function and increase their risk to have high blood pressure. We want to collect information from participants to help explain why this injury can cause future problems, including Chronic Kidney Disease (CKD) which may help us prevent these health problems.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 36 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)
Study Start Date : April 2008
Actual Primary Completion Date : July 2009
Actual Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
a
those with previous history of Acute kidney injury


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Children 2-20 years old with history of acute kidney injury
Criteria

Inclusion Criteria:

  • Children between age 2-20
  • Decrease in renal function by 25% or greater
  • Renal function has returned to normal

Exclusion Criteria:

  • History of chronic disease
  • Cancer
  • Congenital heart disease
  • Organ Transplantation
  • Liver disease
  • Pulmonary disease
  • Diabetes other primary metabolic condition
  • Severe neurologic impairments
  • Hypertension
  • Auto-immune
  • Infectious disease or renal disease
  • Smokers
  • Renal disease w/primary cause i.e. - HUS or Glomerulonephritis
  • severe allergies including allergy to seafood and/or iodine
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00358306


Locations
Layout table for location information
United States, Alabama
University Of Alabama
Birmingham, Alabama, United States, 35233
Sponsors and Collaborators
University of Alabama at Birmingham
Investigators
Layout table for investigator information
Principal Investigator: David Askenazi, MD UAB Pediatric Nephrology
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: David Askenazi, Principal Investigator, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT00358306    
Other Study ID Numbers: F070309010
First Posted: July 31, 2006    Key Record Dates
Last Update Posted: May 14, 2020
Last Verified: May 2020
Keywords provided by David Askenazi, University of Alabama at Birmingham:
Endothelium
Chronic Kidney Disease
Acute Kidney Injury
Hemolytic-uremic syndrome (HUS)
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Acute Kidney Injury
Renal Insufficiency
Kidney Failure, Chronic
Hemolytic-Uremic Syndrome
Hemolysis
Pathologic Processes
 Urologic Diseases
Uremia
Anemia, Hemolytic
Anemia
Hematologic Diseases
Thrombotic Microangiopathies
Thrombocytopenia
Blood Platelet Disorders